Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Juliette Petit"'
Autor:
Alice Courties, Juliette Petit, Ariane Do, Manon Legris, Inès Kouki, Audrey Pigenet, Pradeep K. Sacitharan, Francois-Paul Ehkirch, Francis Berenbaum, Jérémie Sellam
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
IntroductionOsteoarthritis (OA) is a whole-joint disease characterized by a low-grade inflammation that is involved in both cartilage degradation and subchondral bone remodeling. Since subchondral bone has a cholinergic innervation and that acetylcho
Externí odkaz:
https://doaj.org/article/912b6d705e5b445e814b4cdb659b5432
Autor:
Francis Berenbaum, Catherine Beauvais, Marie Antignac, Sandra Desouches, Juliette Petit, Rose-Marie Poilverd, Régine Baratto, Sylvie Darthout, Karine Louati, Nathalie Deparis
Publikováno v:
RMD Open, Vol 7, Iss 1 (2021)
Objectives To evaluate an intervention to reduce the nocebo effect (NE) when switching from the originator infliximab (OI) to the infliximab biosimilar SB2 in chronic inflammatory rheumatic disease (CIRD).Methods An intervention was built with health
Externí odkaz:
https://doaj.org/article/bdceb0ff675d43a98e7c4e869966cc73
Autor:
Juliette Petit
Cet article étudie les liens entre l’intérieur et l’extérieur des prisons au prisme de l’histoire commune entre radio et détention. Les années 80 sont marquées par l’essor des radios libres et des programmes dédiés aux personnes déte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96d0c14bd1ff49df9510590da5414a4e
http://journals.openedition.org/radiomorphoses/2408
http://journals.openedition.org/radiomorphoses/2408
Publikováno v:
Arthritisrheumatology (Hoboken, N.J.)References. 74(8)
Autor:
Pauline Gury, Pauline Narme, Juliette Petit, Vitalie Roussel, Pierre Bertrand, Serge Bakchine, Nathalie Ehrlé
Publikováno v:
Revue Neurologique. 178:S62
Autor:
Pauline Gury, Pauline Narme, Juliette Petit, Vitalie Roussel, Pierre Bertrand, Serge Bakchine, Nathalie Ehrlé
Publikováno v:
Revue Neurologique. 178:S62
Autor:
Alice Courties, Jérémie Sellam, Juliette Petit, Adeline Cambon-Binder, Ariane Do, L. Sudre, Manon Legris, Francis Berenbaum, Sarah Leite, Geoffroy Nourissat, Uwe Maskos, A. Pigenet
Publikováno v:
Arthritis & rheumatology
Arthritis & rheumatology, Wiley, 2020, ⟨10.1002/art.41429⟩
Arthritis & rheumatology, 2020, ⟨10.1002/art.41429⟩
Arthritis & rheumatology, Wiley, 2020, ⟨10.1002/art.41429⟩
Arthritis & rheumatology, 2020, ⟨10.1002/art.41429⟩
OBJECTIVE The non-neuronal cholinergic system represents non-neuronal cells that have the biochemical machinery to synthetize de novo and/or respond to acetylcholine (ACh). We undertook this study to investigate this biochemical machinery in chondroc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91677db231dd1f3c8fdb238ac041ef51
https://hal-pasteur.archives-ouvertes.fr/pasteur-02935940/file/art.41429.pdf
https://hal-pasteur.archives-ouvertes.fr/pasteur-02935940/file/art.41429.pdf
Publikováno v:
Abstracts Accepted for Publication.
Background Nocebo effect (NE) defines any declared negative side effect of a drug that is non-specific, non-explained by its pharmacokinetic, and non-dose dependant. Recently, it has been pointed out as the main factor that reduces the retention rate
Autor:
Sylvie Dartout, Karine Louati, Juliette Petit, Nathalie Deparis, Francis Berenbaum, C. Beauvais, Rose Marie Poilverd, Marie Antignac, Régine Baratto
Publikováno v:
Saturday, 15 June 2019.
Background: Nonspecific subjective adverse effects (NSAE), usually considered as related to a nocebo effect (NE), have been identified as a barrier to the acceptability of switches from biologic originators (BO) to biosimilars (BS). Objectives: To as
Autor:
C. Beauvais, Marie Antignac, Sandra Desouches, Karine Louati, Régine Baratto, Francis Berenbaum, Rose Marie Poilverd, S. Dartout, Juliette Petit, Nathalie Deparis
Publikováno v:
Annals of the Rheumatic Diseases. 79:919.2-920
Background:Nonspecific subjective adverse effects and symptoms (NSAE/NSS), usually considered as related to a nocebo effect (NE), have been identified as a barrier to the acceptability of switches from biologic originators (BO) to biosimilars (BS) in